NanoViricides Posts $4.0M Loss in H1 FY2026, Narrows Deficit 23% From Year-Ago

NanoViricides reported a net loss of $4.0 million for the six months ending December 31, compared with a $5.2 million loss in the same period a year earlier. The biotech company posted a loss of $0.22 per share for the first half of fiscal 2026, an improvement from the $0.36 per share loss recorded in the year-ago period. Read more earnings reports.

Operating expenses dropped to $4.0 million from $5.2 million year-over-year. Research and development spending fell 32% to $2.1 million from $3.1 million, while total operating expenses declined 23% during the six-month period.

For the three months ending December 31, NanoViricides posted a net loss of $2.2 million, compared with a $2.0 million loss in the prior-year quarter. Second-quarter operating expenses rose 8% to $2.2 million from $2.1 million, driven by a slight uptick in general and administrative costs even as R&D spending declined.

Cash and cash equivalents stood at $5.2 million as of December 31, up from $1.6 million six months earlier. The company raised $7.3 million through financing activities during the first half of fiscal 2026, compared with $4.0 million in the year-ago period.

NanoViricides burned through $3.6 million in operating cash flow for the six months ending December 31, an improvement from the $4.8 million burn rate in the prior-year period. Capital expenditures totaled $84,316, slightly higher than the $46,764 spent in the year-ago period.

Total assets increased to $12.3 million from $8.8 million at the end of June. Property, plant and equipment declined to $6.7 million from $6.8 million over the same period. Current liabilities fell to $1.2 million from $1.3 million.

Stockholders' equity jumped to $11.1 million as of December 31 from $7.5 million six months prior. The company issued 5.0 million new shares during the period, bringing total shares outstanding to 21.6 million compared with 16.6 million at the end of June. Additional paid-in capital rose to $163.9 million from $156.4 million.

The accumulated deficit widened to $152.8 million from $148.8 million over the six-month period. Weighted average shares outstanding increased 31% to 18.5 million for the first half of fiscal 2026 from 14.1 million in the prior-year period.